EXECUTIVE ENGAGEMENTS
POOL
5142
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
822
Interactions with Platform & by Email
PARTICIPANTS
154
Unique # Participated
VALIDATIONS
33
Responses Validated*
COMPANIES
46
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
196
EDITION
7
PRICE
USD 5450
CODE
MCP16758
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Rheumatology Therapeutics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$53.7 Billion by 2027, growing at a CAGR of 2.5% over the analysis period 2020-2027. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is projected to record a 2.4% CAGR and reach US$45.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Steroidal Anti-Inflammatory Drugs (Nsaids) segment is readjusted to a revised 3% CAGR for the next 7-year period.
The Rheumatology Therapeutics market in the U.S. is estimated at US$13.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.6 Billion by the year 2027 trailing a CAGR of 2.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 2.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.
In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 3.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6 Billion by the year 2027.
SELECT PLAYERS
AbbVie, Inc.; Amgen, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Janssen Biotech, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.; Sanofi SA; Takeda Pharmaceutical Co., Ltd.
SEGMENTS
» Disease Indication (Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis, Other Disease Indications) » Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) » Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs, Other Drug Classes) » Route of Administration (Oral Route, Parenteral Route, Topical)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Uric Acid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Osteoarthritis (OA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Osteoarthritis (OA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Osteoarthritis (OA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Rheumatoid Arthritis (RA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Rheumatoid Arthritis (RA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Rheumatoid Arthritis (RA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Psoriatic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 46 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com